Navigation Links
WuXi PharmaTech Expands Collaboration for Fully Integrated Services
Date:10/16/2008

SHANGHAI, China, Oct. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V. (J&JPRD) to expand its pharmaceutical R&D services collaboration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOG )

The new broad agreement aims to deepen the already long-standing relationship between J&JPRD and WuXi PharmaTech. WuXi, already a preferred research services provider to J&JPRD for discovery chemistry, will now provide integrated research services in the area of discovery chemistry, discovery biology, chemical and analytical development services, formulation, and preclinical and bio-analytical services, to enhance drug discovery and shorten development timelines.

Commenting on the agreement, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "We are very pleased to expand our partnership with J&JPRD. This agreement leverages WuXi's strong R&D capabilities from early stage discovery to commercial production to deliver reliable, high quality and cost-efficient services to J&JPRD. Our partnership demonstrates the strength of our innovation driven and fully integrated R&D service platform."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

Form more information, please contact:

Sherry Shao

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com

Juliane Snowden

Vice President of Investor Relations

Burns McClellan

Tel: +1-212-213-0006

Email: jsnowden@burnsmc.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
7. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
11. WuXi PharmaTech 2007 Annual Report Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: